| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.86 [0.72, 1.02] | | < 1 | | 0% | 1 study (1/-) | 95.5 % | NA | not evaluable | | crucial | - |
| progression or deaths (PFS) | 0.78 [0.65, 0.93] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 1.48 [1.10, 2.00] | | > 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (grade 3-5) | 1.53 [1.01, 2.33] | | < 1 | | 0% | 1 study (1/-) | 2.3 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 3.74 [1.75, 7.95] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 2.02 [1.42, 2.89] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.16 [0.83, 1.61] | | < 1 | | 0% | 1 study (1/-) | 19.7 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 1.19 [0.85, 1.67] | | < 1 | | 0% | 1 study (1/-) | 15.4 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 0.98 [0.14, 7.00] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.96 [0.07, 58.70] | | < 1 | | 0% | 1 study (1/-) | 35.1 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.87 [0.63, 1.20] | | < 1 | | 0% | 1 study (1/-) | 79.8 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.98 [0.38, 2.50] | | < 1 | | 0% | 1 study (1/-) | 51.7 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 1.97 [0.18, 21.78] | | < 1 | | 0% | 1 study (1/-) | 29.2 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.24 [0.01, 5.43] | | < 1 | | 0% | 1 study (1/-) | 81.1 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.32 [0.03, 3.14] | | < 1 | | 0% | 1 study (1/-) | 83.3 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 1.96 [0.07, 58.70] | | < 1 | | 0% | 1 study (1/-) | 35.1 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.38 [0.43, 4.39] | | < 1 | | 0% | 1 study (1/-) | 29.3 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.87 [0.33, 2.28] | | < 1 | | 0% | 1 study (1/-) | 61.3 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 1.96 [0.07, 58.70] | | < 1 | | 0% | 1 study (1/-) | 35.1 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.96 [0.07, 58.70] | | < 1 | | 0% | 1 study (1/-) | 35.1 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 5.92 [0.30, 118.67] | | < 1 | | 0% | 1 study (1/-) | 12.5 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 3.94 [0.18, 87.61] | | < 1 | | 0% | 1 study (1/-) | 19.6 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.68 [0.38, 1.24] | | < 1 | | 0% | 1 study (1/-) | 89.7 % | NA | not evaluable | | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.96 [0.07, 58.70] | | < 1 | | 0% | 1 study (1/-) | 35.1 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 0.98 [0.02, 49.53] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.85 [0.31, 2.38] | | < 1 | | 0% | 1 study (1/-) | 61.8 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 1.96 [0.07, 58.70] | | < 1 | | 0% | 1 study (1/-) | 35.1 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.94 [0.67, 1.32] | | < 1 | | 0% | 1 study (1/-) | 63.0 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 3.94 [0.18, 87.61] | | < 1 | | 0% | 1 study (1/-) | 19.6 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.96 [0.31, 28.57] | | < 1 | | 0% | 1 study (1/-) | 17.6 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 5.92 [0.30, 118.67] | | < 1 | | 0% | 1 study (1/-) | 12.5 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 3.95 [0.44, 35.56] | | < 1 | | 0% | 1 study (1/-) | 11.1 % | NA | not evaluable | | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 0.98 [0.02, 49.53] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 3.99 [0.84, 18.92] | | < 1 | | 0% | 1 study (1/-) | 4.1 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.80 [0.52, 1.24] | | < 1 | | 0% | 1 study (1/-) | 83.8 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.98 [0.02, 49.53] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 1.11 [0.42, 2.90] | | < 1 | | 0% | 1 study (1/-) | 42.0 % | NA | not evaluable | | non important | - |
